Man, these guys are strict. There's a lot of events that Immuron does not notify the market about, even though just about every other public biotech does. For example, patent news? Most biotechs PR it if it's a significant patent. Immuron has at least once so far as I can recall, but most of the time, they don't.
Which leads me this, from the 20-F in October 2018 regarding the NASH trial:
"We are currently completing the final analysis of the samples, data generated, and additional tests performed and should have the final clinical study report completed and submitted to the FDA by the end of 2018."
SURELY Immuron would notify the market if they submitted the final NASH clinical study report to the FDA, right?
Immuron's Intepretation of News Events
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
